SecBot SecBot
6-K ·Filed Aug 10, 2026

ALC

ALCON INC
BULLISH
Impact 6/10
Horizonweeks Processed3mo ago SEC0001167379-26-000030
Notable filing: 6-K
Actionable Insight ▲ Bullish

The headline EPS miss is noise from a non-cash impairment; the core results and raised guidance are the real signal. Traders should focus on the 11% core EPS growth and the raised full-year outlook for core operating margin (+90 to +190 bps) and core EPS growth (+12% to +15%). The $1.5B buyback authorization provides downside support. Monitor the Q3 2026 earnings call for updates on tariff refund realization and the PowerVision discontinuation's impact on R&D spend.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$75.35
T+0 close · Aug 10, 2026 · via day close
Latest settled
+2.60%
T+60 · $77.31
Vs SPY
+3.09%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 11 $75.35entry
  2. T+1 · 3mo ago −2.35%α −2.60% · $73.58
  3. T+5 · 3mo ago −2.39%α −1.99% · $73.55
  4. T+20 · 2mo ago −9.18%α −8.12% · $68.43
  5. T+60 · 13d ago +2.60%α +3.09% · $77.31
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Alcon reported Q2 2026 net sales of $2.8 billion, up 8% YoY (7% constant currency), driven by strong performance across Surgical and Vision Care segments. However, reported operating income collapsed to $11 million (from $247 million) and diluted EPS was $0.00 due to a $505 million non-cash impairment charge from discontinuing the PowerVision IOL programs. Core diluted EPS (non-IFRS) rose 11% to $0.84, and the company raised its full-year guidance for core operating margin and core diluted EPS growth, signaling underlying operational strength despite the one-time charge. The market should focus on the core results and raised guidance, which are positive, while the impairment is a non-cash item that does not affect cash flow or long-term objectives.

Key Facts

  • Q2 2026 net sales of $2.8 billion, up 8% reported / 7% constant currency vs Q2 2025
  • Reported diluted EPS of $0.00 vs $0.35 in Q2 2025, due to a $505 million non-cash impairment charge from discontinuing PowerVision IOL programs
  • Core diluted EPS (non-IFRS) of $0.84, up 11% vs Q2 2025
  • Core operating margin improved 150 bps to 20.6% (reported) / 160 bps (constant currency)
  • Full-year 2026 guidance raised: core operating margin change now +90 to +190 bps (from +70 to +170 bps); core diluted EPS growth now +12% to +15% (from +10% to +13%)
  • Net cash from operations of $928 million in H1 2026, up from $889 million in H1 2025
  • Free cash flow of $693 million in H1 2026, up from $681 million
  • Returned $538 million to shareholders YTD through dividends and share repurchases
  • $1.5 billion share repurchase authorization approved in May 2026, with ~$1.2 billion remaining
  • Terminated proposed acquisition of LENSAR, Inc. on March 16, 2026

Financial Impact

Q2 2026 net sales $2.8B (+8% YoY); reported operating income $11M (vs $247M); core operating income $574M (+17%); reported diluted EPS $0.00 (vs $0.35); core diluted EPS $0.84 (+11%); H1 2026 operating cash flow $928M (+$39M YoY); free cash flow $693M (+$12M YoY)

revenueepsoperating incomeoperating margincash flow

Risk Factors

  • Tariff impact of $40M-$90M expected for FY 2026, with ongoing uncertainty from U.S. trade policy
  • PowerVision program discontinuation may signal broader R&D pipeline risk or future impairment charges
  • Continued softness in the cataract market could pressure Surgical consumables growth
  • Foreign currency volatility could impact reported results, with expected +90 bps tailwind to sales growth in FY 2026

Market Snapshot

Exchange
NYSE
Sector
Ophthalmic Goods
Analyst Consensus
80% bullish (20 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001167379-26-000030
Document: q22026pressrelease.htm0001167379-26-000030
Document: alc-20260630.htm0001167379-26-000030
Document: 0001167379-26-000030-index-headers.html0001167379-26-000030
Document: 0001167379-26-000030-index.html0001167379-26-000030
Document: 0001167379-26-000030.txt0001167379-26-000030

Track record

5 reports on ALC

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 10, 20266d ago 6-K Neutral 5/10 Entry $72.46 Now $73.64 +1.63% settles Feb 9
  2. Nov 6, 202610d ago Institutional Cluster Mixed 3/10 Entry $74.94 Now $73.64 −1.73% settles Feb 4
  3. Aug 10, 202614w ago 6-K Bullish 6/10 Viewing Entry $75.35 to $77.31 Now $73.64 −2.27% ▲ +2.60% +3.09% vs SPY
  4. Jun 26, 202620w ago Court Ruling Bullish 5/10 Entry $67.61 to $65.39 Now $73.64 +8.92% ▼ −3.28% −6.90% vs SPY
  5. Jun 26, 202620w ago Court Ruling Bullish 5/10 Entry $67.80 to $64.87 Now $73.64 +8.61% ▼ −4.32% −8.81% vs SPY
Showing 5 of 5

US Market Status

Market Closed · Opens Wed (11h 31m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 10, 2026